🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

BRIEF-Aurinia Pharma presents voclosporin remission data

Published 2017-06-16, 08:14 a/m
© Reuters.  BRIEF-Aurinia Pharma presents voclosporin remission data
AUPH
-

June 16 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :

* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017

* Aurinia Pharmaceuticals Inc - no unexpected safety signals nor adverse events were observed and voclosporin was generally well-tolerated

* Aurinia Pharmaceuticals - there were no electrolyte changes in treatment groups, mean blood pressure was similar across treatment groups through 48 weeks

* Aurinia Pharmaceuticals - voclosporin treated groups showed statistically significant improvement over control group in speed, rates of complete, partial remission

* Aurinia Pharma- voclosporin treated groups demonstrated statistically significant improvement over control group in speed, rates of complete, partial remission Source text for Eikon: ID:nBwbSVbMLa Further company coverage: AUP.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.